Literature DB >> 16986820

Systematic overview of drug interactions with antidepressant medications.

Carmine Nieuwstraten1, N Renee Labiris, Anne Holbrook.   

Abstract

OBJECTIVE: Antidepressants are commonly used drugs with potential for numerous drug interactions. This study aims to systematically review the literature on drug interactions with antidepressants.
METHODS: We searched MEDLINE (1966 to November 2003) and EMBASE (1980 to 2003), using the heading drug interactions combined with individual antidepressant names. We restricted searches to English-language articles and human studies. We screened drug interaction texts and review articles for relevant studies. We included articles reporting original human data on drug interactions with antidepressants commonly used in North America. Articles were independently evaluated by 2 reviewers on clinical effect, clinical significance, and quality of evidence. Discrepancies were resolved by consensus.
RESULTS: There were 904 eligible interactions, involving 9509 patients, for a total of 598 summary interactions. Of these, 439 (73%) demonstrated an interaction, 148 (25%) had no effect, and 11 (2%) had conflicting evidence. For 510 interactions (85%), the quality of evidence was poor. It was fair for 67 (11%) interactions and good for 10 (2%) interactions. There were no interactions with excellent quality of evidence. There were 145 (24%) interactions of major clinical significance. These were predominantly hypertensive emergencies and serotonin syndrome. Most interacting drugs had central nervous system (CNS) activity. As expected, monoamine oxidase inhibitors (MAOIs) appear to be the most problematic family in terms of potential for serious drug interactions.
CONCLUSIONS: Drug interactions with antidepressants are an important cause for concern, but this concern is based primarily on poor evidence. We recommend caution when combining antidepressants with other CNS drugs, particularly when coadministering MAOIs with other substances.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16986820     DOI: 10.1177/070674370605100506

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  12 in total

Review 1.  [Herb-drugs interactions].

Authors:  Johannes Freudenstein; Thomas Nisslein
Journal:  Wien Med Wochenschr       Date:  2007

Review 2.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data.

Authors:  Clare Ringland; Andrea Mant; Patricia McGettigan; Philip Mitchell; Christopher Kelman; Nicholas Buckley; Sallie-Anne Pearson
Journal:  Br J Clin Pharmacol       Date:  2008-07-08       Impact factor: 4.335

Review 4.  Depression in adults: drug and physical treatments.

Authors:  Andrea Cipriani; Corrado Barbui; Rob Butler; Simon Hatcher; John Geddes
Journal:  BMJ Clin Evid       Date:  2011-05-25

Review 5.  Antidepressants for the treatment of chronic pain.

Authors:  Bénédicte Verdu; Isabelle Decosterd; Thierry Buclin; Friedrich Stiefel; Alexandre Berney
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  St John's wort for major depression.

Authors:  Klaus Linde; Michael M Berner; Levente Kriston
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

7.  Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain.

Authors:  Ibrahim Eren; Mustafa Naziroğlu; Arif Demirdaş
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

8.  Neuroprotective potential of escitalopram against behavioral, mitochondrial and oxidative dysfunction induced by 3-nitropropionic acid.

Authors:  Shruthi Shetty; Ashwini Hariharan; Trupti Shirole; Aarti G Jagtap
Journal:  Ann Neurosci       Date:  2015-01

9.  Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network.

Authors:  Jialiang Huang; Chaoqun Niu; Christopher D Green; Lun Yang; Hongkang Mei; Jing-Dong J Han
Journal:  PLoS Comput Biol       Date:  2013-03-21       Impact factor: 4.475

Review 10.  Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs.

Authors:  Mustafa Nazıroğlu; Arif Demirdaş
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.